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INTRODUCTION
Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer 1, 2 .
Although robust and often dramatic clinical responses are achieved with platinum-based firstline treatment, recurrence/progression usually occurs early and is resistant to available treatments 3 . Outcomes in patients with stage IV disease remain poor with a median overall survival that rarely exceeds one year 1, 4 .
Immunotherapy has led to a paradigm-shift in the treatment of solid tumors 5, 6 . SCLC seems a particularly attractive target for immunotherapy. Paraneoplastic neurological syndromes (PNSs) are common in SCLC and are characterized by anti-cancer immune responses, which become clinically visible by off-tumor immune consequences against neuronal antigens, ectopically expressed by cancer cells and physiologically by the normal nervous system 7 . The better cancer specific survival outcomes in patients with autoimmune disease points to a protective effect, linked to these cross-reactive immune responses 8, 9 . Moreover, high mutational load has been linked to benefit from immunotherapy 10 and SCLC falls into this category 2, 11, 12 , most likely as a result of the tight association with tobacco smoking.
Therefore, harnessing the immune system to fight SCLC seems a potentially promising strategy, although the best approach is currently uncertain.
Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that blocks CTLA-4 13 , and has been tested in SCLC. A phase II trial 14 , showed a trend to improved overall survival with phased ipilimumab added to a platinum doublet. However, the confirmatory phase III trial 15 comparing ipilimumab and chemotherapy vs chemotherapy did not confirm better overall survival after chemoimmunotherapy. More recently, anti-PD-1 agents have also been tested in SCLC. Nivolumab (alone and in combination with ipilimumab) showed antitumor activity in SCLC patients with relapsed disease 16 . In a phase I trial, Pembrolizumab use led to objective responses greater than 30% of patients 17 .
Nonetheless, the majority of patients with SCLC do not benefit from checkpoint inhibitors and the absence of predictive biomarkers for patient selection may have contributed to negative trial results 15 . Additionally, clinically relevant autoimmune toxicity has been reported, including severe neurological PNS 14, 16, 18 increasing the level of caution that is needed when investigating immunotherapy in SCLC. PD-L1 immunohistochemical expression, which is predictive for benefit from modulation of PD1/PDL1 in Non-Small Cell Lung cancer, does not appear to correlate with outcome in SCLC 16, 17 . A confounding effect for the evaluation of PD-L1 status in the tumor is limited access to tissue due to small biopsy material or cytology diagnostic specimens, a well-recognized problem in SCLC 19 . Therefore, the need to develop predictive biomarkers remains an urgent priority in SCLC.
With the aim of identifying potential biomarkers, we previously performed an exploratory analysis of the phase II ICE trial with a single cohort of patients treated with chemotherapy and ipilimumab. In this single arm study, positivity of autoantibodies at baseline was associated with improved outcomes 18 .
In the current study we added a 'control' cohort treated with standard chemotherapy in order to assess the predictive vs. prognostic role of the neuronal autoantibodies. We also analyzed changes in autoantibody detection during treatment to evaluate the potential utility of serial sampling. We assessed the impact of clinical variables on survival. Table 2 illustrates the association between clinical variables and OS combining both cohorts. PS:0 vs. PS>0 (p=0.019), limited stage (p=0.003) and response to first line chemotherapy (p<0.001) were associated with a significantly improved survival (Table 2) .
RESULTS

Patients' characteristics and outcomes
Neuronal autoantibody detection
Neuronal autoantibodies (NAA) were detected at baseline in 25 patients (53.2%) in C1 and in 20 patients (52.6%) in C2. In both cohorts, the most prevalent autoantibody was anti-Sox1 (38.3% in C1 and 34.2% in C2), followed by anti-HuD and anti-Yo (Table 3 , Figure 1 -left).
Globally, 13 patients out of the 45 with baseline NAA (28.9%) showed 2 or more reactivities at any time-point (Supplementary Table 1 ); of these, 11 patients (24.5%), had 2 or more types of autoantibody at baseline. Eight patients (17.8%) in C1 showed 2 or more reactivities; one of these patients was positive at baseline for anti-Sox1, but became also positive for anti-Yo after 3 cycles of chemotherapy. Five patients (11.1%) in C2 showed 2 or more reactivities; one of these patients was positive at baseline for anti-Yo, and became also positive for antiGad65 after 8 weeks of treatment. Anti-Yo and Anti-Sox1 detection were associated with another NAA in 7/12 patients (58.3%) and 9/32 patients (28.1%), respectively. One patient showed reactivity for 4 NAA: anti-Sox1, anti-amphiphysin, anti-Ri and anti-HuD. In Figure 1 (right) we illustrate the different multi-reactivities of NAA in patients of both cohorts.
Association between neuronal autoantibodies and clinical characteristics and outcomes
We We assessed the association of NAAs with clinical outcomes. In patients with pre-treatment NAAs we observed a trend for better overall survival when both cohorts were analyzed (Figure 2 ). This association was lost when the analysis was restricted to stage IV patients and was not observed in patients from C2. No effect from baseline autoantibody presence was observed on objective response rates or PFS (Table 4) .
We then tried to gain insight whether the breadth rather than simply examining presence or absence of reactivity against NAAs might link to outcomes. We segregated patients with reactivity to exactly one, as opposed to >1 NAA. Unexpectedly, the presence of only 1 NAA single reactivities was not associated with ipilimumab-related adverse events in cohort 2 (colitis, fatigue and rash) nor neurological events.
We then evaluated the association between NAA against individual antigens and clinical outcomes. In patients treated with ipilimumab and chemotherapy, OS was 7.8m (95% CI 2.2- In the multivariate analysis in C2 for OS, including poor PS and lack of response to first line treatment, having 2 or more vs 1 NAA, remained independently associated with poor outcome (HR: 3.4; p-value: 0.033).
Titers of NAA change upon response to treatment
We quantified the titers of NAAs at each time point (Supplementary Figure 1) . Overall in 31
(68.9%) of the 45 patients with NAAs at baseline, titers decreased after treatment initiation ( Figure 4 ). In 22 out of these (48.9%), titers remained lower than baseline at the 3 rd time point (progression) and in 9 patients (20%) they increased again. In 6 patients (13.4%), titers increased after treatment; of these, 2 patients (4.5%) maintained higher titers at progression and in 4 patients (8.9%) titers decreased. Autoantibody titers remained unchanged in 2 patients (4.5%). Variable patterns of change were observed in the 6 (13.4%) remaining patients (example shown in Supplementary Figure 2 
DISCUSSION:
SCLC is an aggressive disease with poor outcome. Tumor-associated immunological events have been classically described in SCLC in the form of paraneoplastic syndromes, which clinically lead to neurological adverse events 20 . Autoantibodies directed to neuronal antigens abnormally expressed in the tumor are detected in patients with PNS and are used as a diagnostic tool in this setting 21, 22 . NAAs have been described to be immune effectors of neurological dysfunction in the case of membranous antigens (i.e. calcium channel antibodies) 23 . Intracellular antigens may also be subject to a cytotoxic T-cell response, where the accompanying antibody production may not be per se pathogenic [24] [25] [26] [27] . Notably Consistent with previously reported series 22, 30 , in the current study anti-Sox1 was the most prevalent tumor-associated NAA. Unexpectedly, anti-Yo was the second most prevalent NAA;
although it is usually associated with ovarian and breast cancer, it has also been described in lung cancer 34, 35 . Moreover, anti-Gad65, usually linked to autoimmune diabetes 36 , was detected in 3 patients in C1 and in 2 patients in C2. None of these patients had a history of type 1 diabetes in our study. It could be argued that these detections could be due to technical issues with the immune-blot assay. However, this method has been used in previous studies and shows good performance in 'screening' settings such as our work 37, 38 . Furthermore, the fact of having serial samples for the same patient allowed us to use these as internal controls for the positive cases (Supplementary Figure 1) .
The presence of NAAs has been linked to early stages and in turn to better outcome 28, 29, 32, 39 .
The concomitant cytotoxic T cell response 27,40-42 might contribute to a degree of tumor control, sparing the immune privileged nervous system 43, 44 . In the case of SCLC-associated PNS, the diagnosis of the neurological disease often antedates that of the tumor 20, 45 ,
suggesting that the immune system is able to detect the presence of SCLC before the cancer develops metastases 39, 46 . This concept is also supported in other studies where the presence of autoantibodies was independently associated with earlier stages 29, 47 . Accordingly, in our series we observed a trend towards an association of NAAs (specifically anti-Sox1) with earlier stage.
When we analyzed the presence of multiple against single NAA reactivities, we observed that 28% of patients had more than one reactivity. This is consistent with previous literature. In a large series of 60,000 subjects with suspicion of PNS, 553 (0.9%) were positive for any NAA 21 ; among these, 31% had more than 1 autoantibody. Intriguingly, in our series, patients with multiple reactivities had a significantly shorter PFS and OS when treated with the combination of chemotherapy and ipilimumab. The presence of coexisting autoantibodies reflects a multifaceted response to the different inmunogenic onconeural proteins expressed in tumors. The impact of multiple vs. single reactivities has not been reported previously.
Although small numbers are included in this analysis, if multiple reactivities reflected heterogeneity within the tumor and consequently subclonal T cell responses, it has been described that checkpoint inhibitor treatment might be less effective in this scenario 48 , but this is hypothesis generating and requires validation.
We analyzed the patterns of change in NAA titers in patients treated with chemotherapy vs.
those treated with chemoimmunotherapy. In most patients the NAA titers decreased after initiation of therapy. We note that the addition of ipilimumab to chemotherapy did not appear to affect this outcome; this is in contrast with boosting of humoral response to vaccination against infectious agents that has previously been reported 49 and also to the effect of ipilimumab on tumor-specific T cells that appear to be induced de novo 50 Consistent with the concept that removal of immunogen is linked with a decrease in antibody titer, we observed a trend to a longer OS in those patients whose titer of NAA decreased progressively after treatment with chemotherapy; this was irrespective of whether ipilimumab was administered.
Intriguingly however, our data also raise the possibility of a quite different immunological consequence: subgroup analysis of the small number of patients with increasing titers after initiation of chemotherapy identified a longer than median PFS; this raises the question of whether enhanced immune response due to intracellular antigen exposure after cytotoxic chemotherapy may lead to a better T-cell response and in turn to increased antibody production. A dataset in melanoma reported by the Wolchok group is consistent with this concept, as the presence or development of antibodies and T-cell responses to NyEso1 appeared to identify a group of patients, who did well after ipilimumab treatment 63 . We conclude that further detailed studies are needed, which link the humoral responses and cellular responses in cancer patients, both after standard treatment and immunotherapy.
In summary, we were able to confirm the prognostic role of NAA probably related with disease control in early stage derived from tumor directed immune response. To our knowledge, we demonstrate for the first time that treatment with ipilimumab combined with chemotherapy in SCLC does not induce differential changes in NAA titers and their levels appear to mainly reflect the disease burden. The predictive role of NAAs and B cell immune response warrants further investigation in SCLC.
PATIENTS AND METHODS
Study populations
We retrospectively analyzed the data and serum from 85 SCLC patients from two independent cohorts. The first cohort included 47 patients with SCLC treated with first-line standard chemotherapy (platinum -etoposide), recruited within research projects in Hospital del Mar, Barcelona, and previously reported [64] [65] [66] . We included patients with early and locally advanced disease as well as stage IV patients, in order to investigate the impact of stage in the detection of NAAs. From this series we had a control population, from age-and sex-matched healthy donors (N: 30) to the study population. The second cohort were patients included in the ICE trial 18 , where 38 chemo-naïve stage IV SCLC patients were treated with ipilimumab in combination with carboplatin-etoposide. Serum samples at baseline and subsequent time points (before, during and after treatment) were collected from each patient. Complete clinical data and follow up information was available for every patient.
Sample analysis was approved for the cohort 1 by the local ethics committee and for cohort 2 within the trial ethics committee.
Sampling
Serum samples were collected for C1 before treatment initiation (baseline), at first response assessment and at progression. For C2, samples were collected at baseline, at 3 and 6 months when feasible. All patients in C1 had 3 serial serum samples (baseline, first response assessment and progression timepoints). Out of the 38 patients in C2, 20 had 2, 11 had 3, and 6 had 4 serial timepoints (all included baseline). One patient in C2 had no available serum samples. Serum from 3 healthy volunteers was used as negative controls and serum from a SCLC patient with a known anti-HuD associated PNS as a positive control.
Whole blood samples were collected by standard venipuncture techniques using serum separator tubes. Samples were allowed to clot for 30 minutes at room temperature before centrifugation for 10 minutes at 1000g at 4ºC. Following centrifugation, the supernatant (serum) was immediately removed and assayed immediately or aliquoted and stored frozen at -80ºC until further use. 
Assessment of autoantibodies
Statistical analysis
